+

WO1999009965A3 - Anti-inflammatory agent - Google Patents

Anti-inflammatory agent Download PDF

Info

Publication number
WO1999009965A3
WO1999009965A3 PCT/JP1998/003692 JP9803692W WO9909965A3 WO 1999009965 A3 WO1999009965 A3 WO 1999009965A3 JP 9803692 W JP9803692 W JP 9803692W WO 9909965 A3 WO9909965 A3 WO 9909965A3
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
group
inflammatory agent
formula
ring
Prior art date
Application number
PCT/JP1998/003692
Other languages
French (fr)
Other versions
WO1999009965A2 (en
Inventor
Hiroyuki Odaka
Yu Momose
Original Assignee
Takeda Chemical Industries Ltd
Hiroyuki Odaka
Yu Momose
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd, Hiroyuki Odaka, Yu Momose filed Critical Takeda Chemical Industries Ltd
Priority to CA002300813A priority Critical patent/CA2300813A1/en
Priority to EP98938913A priority patent/EP1007038A2/en
Priority to AU87479/98A priority patent/AU8747998A/en
Publication of WO1999009965A2 publication Critical patent/WO1999009965A2/en
Publication of WO1999009965A3 publication Critical patent/WO1999009965A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

An anti-inflammatory agent which affects by way of a TNF-α inhibitory action and comprises a compound of formula (I) wherein R represents a hydrocarbon group that may be substituted or a heterocyclic group that may be substituted; Y represents a group of the formula -CO-, -CH(OH)-, or -NR3- where R3 represents an alkyl group that may be substituted; m is 0 or 1; n is 0, 1 or 2; X represents CH or N; A represents a chemical bond or a bivalent aliphatic hydrocarbon group having 1 to 7 carbon atoms; Q represents oxygen or sulfur; R1 represents hydrogen or an alkyl group; ring E may have further 1 to 4 substituents, which may form a ring in combination with R1; L and M respectively represent hydrogen or may be combined with each other to form a chemical bond or a salt thereof.
PCT/JP1998/003692 1997-08-21 1998-08-20 Anti-inflammatory agent WO1999009965A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002300813A CA2300813A1 (en) 1997-08-21 1998-08-20 Anti-inflammatory agent
EP98938913A EP1007038A2 (en) 1997-08-21 1998-08-20 Anti-inflammatory agent
AU87479/98A AU8747998A (en) 1997-08-21 1998-08-20 Anti-inflammatory agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9/225302 1997-08-21
JP22530297 1997-08-21

Publications (2)

Publication Number Publication Date
WO1999009965A2 WO1999009965A2 (en) 1999-03-04
WO1999009965A3 true WO1999009965A3 (en) 1999-05-20

Family

ID=16827222

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1998/003692 WO1999009965A2 (en) 1997-08-21 1998-08-20 Anti-inflammatory agent

Country Status (4)

Country Link
EP (1) EP1007038A2 (en)
AU (1) AU8747998A (en)
CA (1) CA2300813A1 (en)
WO (1) WO1999009965A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364736B2 (en) 2001-06-26 2008-04-29 Amgen Inc. Antibodies to OPGL
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US9060843B2 (en) 2005-07-18 2015-06-23 Tearscience, Inc. Method and apparatus for treating gland dysfunction employing heated medium
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003508391A (en) 1999-08-31 2003-03-04 マキシア・ファーマシューティカルズ・インコーポレイテッド Benzylidene-thiazolidinediones and analogs and their use in treating diabetes
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US20030060488A1 (en) * 2000-02-10 2003-03-27 Yasuo Sugiyama Drug comprising combination
AU2001247233A1 (en) * 2000-02-24 2001-09-03 San Diego State University Ppar gamma agonists for the treatment of liver inflammatory disorders
WO2002072009A2 (en) 2001-03-07 2002-09-19 Maxia Pharmaceuticals, Inc. Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
JP2004523571A (en) 2001-03-08 2004-08-05 マキシア・ファーマシューティカルズ・インコーポレイテッド RXR activating molecule
US7071218B2 (en) 2001-11-15 2006-07-04 Incyte San Diego Incorporated N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases
GB0128138D0 (en) * 2001-11-23 2002-01-16 King S College London Pharmaceutical use
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
WO2008027069A1 (en) 2006-08-21 2008-03-06 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction employing fluid
US9763827B2 (en) 2013-04-30 2017-09-19 Tear Film Innovations, Inc. Systems and methods for the treatment of eye conditions
EP3744391B1 (en) 2013-04-30 2023-03-01 Alcon Inc. Systems for the treatment of eye conditions
US10974063B2 (en) 2016-06-30 2021-04-13 Alcon Inc. Light therapy for eyelash growth

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035108A1 (en) * 1994-06-22 1995-12-28 The Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
WO1996024350A1 (en) * 1995-02-10 1996-08-15 Schering Aktiengesellschaft Pharmaceutical preparations for tumour necrosis factor (tnf) inhibition
WO1996034943A1 (en) * 1995-05-04 1996-11-07 City Of Hope Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states
DE19540475A1 (en) * 1995-10-20 1997-04-24 Schering Ag Chiral methylphenyloxazolidinones
WO1997037688A2 (en) * 1996-04-05 1997-10-16 Takeda Chemical Industries, Ltd. Pharmaceutical combination containing a compound having angiotensin ii and antagonistic activity
WO1997045141A1 (en) * 1996-05-31 1997-12-04 Sankyo Company, Limited Remedy for autoimmune diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035108A1 (en) * 1994-06-22 1995-12-28 The Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
WO1996024350A1 (en) * 1995-02-10 1996-08-15 Schering Aktiengesellschaft Pharmaceutical preparations for tumour necrosis factor (tnf) inhibition
WO1996034943A1 (en) * 1995-05-04 1996-11-07 City Of Hope Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states
DE19540475A1 (en) * 1995-10-20 1997-04-24 Schering Ag Chiral methylphenyloxazolidinones
WO1997037688A2 (en) * 1996-04-05 1997-10-16 Takeda Chemical Industries, Ltd. Pharmaceutical combination containing a compound having angiotensin ii and antagonistic activity
WO1997045141A1 (en) * 1996-05-31 1997-12-04 Sankyo Company, Limited Remedy for autoimmune diseases

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
C. HOFMANN ET AL.: "Altered Gene Expression for Tumor Necrosis Factor-alpha and Its Receptors during Drug and Dietary Modulation of Insulin Resistance", ENDOCRINOLOGY, vol. 134, no. 1, January 1994 (1994-01-01), pages 264 - 270, XP002094464 *
D.SZALKOWSKI ET AL.: "Antidiabetic Thiazolidinediones Block the Inhibitory Effect of Tumor Necrosis Factor-alpha on Differentiation, Insulin-Stimulated Glucose Uptake, and Gene Expression in 3T3-L1 Cells", ENDOCRINOLOGY, vol. 136, no. 4, April 1995 (1995-04-01), pages 1474 - 1481, XP002094465 *
H.ODAKA ET AL.: "EFFECT OF PIOGLITAZONE ON SUCROSE-DETERIORATED DIABETIC STATES IN SPONTANEOUSLY DIABETIC GK RATS", DIALOG(R) FILE 5: BIOSIS PREVIEWS(R) ACCESSION NUMBER 07798952: J. JPN. DIABETES SOC., vol. 34, no. 6, 1991, pages 523 - 530, XP002094468 *
M. SUZUKI ET AL.: "Nephropathy in genetically obese-diabetic Wistar fatty rats - Characterization and prevention", DIALOG(R) FILE 73: EMBASE, ACCESSION NUMBER 07010090: JPN. PHARMACOL. THER., vol. 25, no. 2, 1997, pages 43 - 51, XP002094469 *
P. PERALDI ET AL.: "Thiazolidinediones Block Tumor Necrosis Factor-alpha.induced Inhibition of Insulin Signaling", J. CLIN.INVEST., vol. 100, no. 7, 1 October 1997 (1997-10-01), pages 1863 - 1869, XP002094470 *
R.W.STEVENSON ET AL.: "The thiazolidinedione drug series", THE DIABETES ANNUAL, vol. 9, 1995, pages 175 - 191, XP002094463 *
S.L. GROSSMAN ET AL.: "Mechanisms and clinical effects of thiazolidinediones", EXPERT OPIN. INVEST. DRUGS, vol. 6, no. 8, August 1997 (1997-08-01), pages 1025 - 1040, XP002094471 *
S.S.SOLOMON ET AL.: "Pioglitazone and Metformin Reverse Insulin Resistance Induced by Tumor Necrosis Factor-Alpha in Liver Cells", HORMON. METAB. RES., vol. 29, no. 8, August 1997 (1997-08-01), pages 379 - 382, XP002094467 *
T. YOSHIMOTO ET AL.: "Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats", AM.J.PHYSIOL., vol. 272, no. 6 Part 1, June 1997 (1997-06-01), pages E989 - E996, XP002094466 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364736B2 (en) 2001-06-26 2008-04-29 Amgen Inc. Antibodies to OPGL
US9060843B2 (en) 2005-07-18 2015-06-23 Tearscience, Inc. Method and apparatus for treating gland dysfunction employing heated medium
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction

Also Published As

Publication number Publication date
CA2300813A1 (en) 1999-03-04
AU8747998A (en) 1999-03-16
WO1999009965A2 (en) 1999-03-04
EP1007038A2 (en) 2000-06-14

Similar Documents

Publication Publication Date Title
WO1999009965A3 (en) Anti-inflammatory agent
AU1172999A (en) Novel apoptosis inhibitors
CA2116387A1 (en) Oxazolidinedione derivatives, their production and use
AU3461697A (en) Heterocyclic compounds, their production and use
EP0513387A4 (en) Active oxygen inhibitor
CA2054209A1 (en) Antihyperlipidemic and antiatherosclerotic urea compounds
MY118904A (en) 4-oxo-1, 4-dihydro-3-quinolinecarboxamides as antiviral agents
CA2328780A1 (en) Dihydropyrimidines
UA41290C2 (en) HETEROARYLAMINES, PHARMACEUTICAL COMPOSITION, METHOD OF CHOLINESTERASE INHIBITION IN MAMMALS, METHOD OF MEMORY IMPROVEMENT
EA200100310A1 (en) OXYGEN CONTAINING HETEROCYCLIC COMPOUNDS
WO2003035620A1 (en) Bicyclic compound
EP0945764A3 (en) Photoresist composition
CA2314564A1 (en) Phosphonocephem derivatives, their production and use
CA2014490A1 (en) Diaminoethylene compounds
CA2125549A1 (en) Tetrazole derivatives, their production and use
WO2002000638A8 (en) Substituted phthalides as anti-convulsive drugs
IE851734L (en) Isoindolinyl-alkyl-piperazines
TW324009B (en) Pyrazole condensation ring derivative, its production process and its use as androgen inhibitor
CA2247946A1 (en) Anticachectic composition
CA2128093A1 (en) 4-Aryl-3-(Heteroarylureido)-1,2-Dihydro-2-Oxoquinoline Derivatives as Antihypercholesterolemic and Antiatherosclerotic Agents
ES2120498T3 (en) NEW TETRACYCLIC COMPOUND.
EP0516860A4 (en) Chromone derivative and aldose reductase inhibitor containing the same as active ingredient
IE44180L (en) Azaprostaglandins.
WO2003057215A1 (en) Neurotrophic factor production/secretion accelerator
IE45092L (en) Carbamic acid oxime-esters.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1998938913

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09485640

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2300813

Country of ref document: CA

Ref country code: CA

Ref document number: 2300813

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1998938913

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998938913

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载